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Background:  Since  the  re-emergence  of Chikungunya  virus  (CHIKV)  in  Reunion  in 2005  and  the  recent
outbreak  in the  Caribbean  islands  with  an  expansion  to  the  Americas  the  CHIK  diagnostic  became  very
important.
Objectives:  We  evaluate  the  performance  of  laboratories  regarding  molecular  and  serological  diagnostic
of  CHIK  worldwide.
Study  design:  A panel  of 12  samples  for molecular  and 13  samples  for serology  were  provided  to  60
laboratories  in  40 countries  for  evaluating  the sensitivity  and  speciﬁcity  of  molecular  and serology  testing.
Results:  The  panel  for molecular  diagnostic  testing  was  analysed  by  56  laboratories  returning  60  data
sets  of results  whereas  the  56 and  60 data  sets  were  returned  for IgG  and  IgM diagnostic  from  the
participating  laboratories.  Twenty-three  from  60 data  sets  performed  optimal,  7 acceptable  and  30  sets
of  results  require  improvement.  From  50 data  sets only  one  laboratory  shows  an  optimal  performance  for
IgM detection,  followed  by  9 data  sets  with  acceptable  and  the  rest  need  for improvement.  From  46 IgG
serology  data  sets  20 provide  an optimal,  2 an  acceptable  and  24  require  improvement  performance.  The
evaluation  of  some  of  the  diagnostic  performances  allows  linking  the  quality  of results  to  the  in-house
methods  or  commercial  assays  used.
Conclusion:  The  external  quality  assurance  for  CHIK  diagnostics  provides  a good  overview  on  the  labora-
tory performance  regarding  sensitivity  and  speciﬁcity  for the  molecular  and  serology  diagnostic  required
for the  quick  and  reliable  analysis  of  suspected  CHIK  patients.  Nearly  half of  the  laboratories  have  to
improve  their  diagnostic  proﬁle  to achieve  a better  performance.
d  by  ©  2016  Z. Publishe
. Background
Chikungunya virus (CHIKV) is a mosquito-transmitted single
tranded, positive-sense RNA Alphavirus ﬁrst isolated in Tanzania
n 1953. Sporadic outbreaks were reported from African and Asian
ountries between 1950s and 2004. The last epidemic was recorded
rom 2004 to 2011 spreading from Kenya across the south-western
ndian Ocean region, India, South East Asia to New Caledonia in
he Paciﬁc region [1,2]. In 2013 a ﬁrst local transmission of CHIKV
n Caribbean island Saint Martin was reported and to date CHIKV
aused infections in more than 20 countries of the Caribbean, Cen-
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).
tral and South America and the US in 2014 [3,4,21]. The main reason
for increasing emergence of CHIK worldwide is the international
travel of viremic persons returning to countries where compe-
tent vectors are indigenous. Under this conditions autochthonous
CHIKV outbreaks can occur as was  seen in Italy and France caused
by imported CHIKV from Asia [5,6].
The diagnosis of acute infections is based on the molecular
detection of virus genome or by serological test systems detect-
ing speciﬁc IgM antibodies [7–14]. Commercial detection systems
(ELISA, immunoﬂuorescence assay [IFA] and rapid tests) for detec-
tion of immunoglobulins are available and have been evaluated
[15–19]. Virus culture and isolation of CHIKV is a very sensitive
method but not practicable for routine diagnostic [20]. Since other
virus infections occur in the region like Dengue these have to be
considered for differential diagnosis. A quick and reliable diagnos-
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ic of a CHIK infection is of high importance for the patient. In a
revious study PCR methods showed a good overall performance
hereas serological assays were less sensitive and speciﬁc [23–25].
n evaluation of the laboratories’ performance for CHIK diagnos-
ic seems an efﬁcient procedure to increase the awareness for this
ecent emergence of CHIK in the Americas and Paciﬁc region
. Objectives
The sensitivity and speciﬁcity of CHIKV nucleic assay testing was
valuated with a panel of 12 samples and serology with 13 samples
y diagnostic laboratories worldwide.
. Study design
.1. Participants
Fifty-six laboratories from 40 countries worldwide (Europe (23),
iddle-East (1), Asia (4), Africa (4), Oceania (3) the Americas (3)
nd the Caribbean (2)) participated in the free of charge EQAs orga-
ized by the European Network for diagnostics of ‘Imported’ Viral
iseases (ENIVD) (www.enivd.de).
.2. Molecular diagnostic
12 samples of cell culture supernatants infected with differ-
nt CHIKV strains were used. The EQA panel represented two
ut of three circulating CHIKV genotypes worldwide: CHIKV
train H20235 Saint Martin/2013 (Asian genotype), both strain
36 origin Seychelles (2 × 108 genome equivalents/ml) and strain
162 origin India (1.1 × 108 genome equivalents/ml) represent
he East-Central-South-Africa (ESCA) genotype (the genotype
f the West African strain was not available). To analyse the
ensitivity of molecular diagnostic, CHIKV strain H20235 Saint
artin/2013 was prepared in a tenfold dilution series (1.8 × 108
o 2.2 × 104 copies/ml) in dest. water and lyophilisation reagent
OPS Diagnostics, Lebanon, US). Assay speciﬁcity was  monitored
y related alphaviruses like O’nyong-nyong virus (ONNV) strain
hero (1.9 × 104 copies/ml), Sindbis virus (SINV) strain Edgar 339
7.5 × 106 copies/ml) and Dengue virus (DENV-2) strain VR-345
8.3 × 104 copies/ml). Two  samples of human plasma were used
or negative controls.
All virus samples were inactivated by heat (56 ◦C, 1 h) and
amma  irradiation 25–30 kgray (Synergy Health Radeberg GmbH,
adeberg, Germany). Samples of 200 l were coded before freeze
rying in glass vials with plugs (SP Industries, US) in a freeze dryer
Epsilon 2-6D, Martin Christ Gefriertrocknungsanlagen GmbH,
ermany) monitored by process recording software (CHRIST LPC-
2 (LSC) SCADA) and stored at 4 ◦C in the dark. Sets of freeze-dried
amples were pretested by two expert laboratories.
.3. Serological diagnostic
CHIK sera were either IgM/IgG positive or IgG positive only.
or analysing assay sensitivity a serial dilution series (1:2–1:16)
ith serum CHIK sero IgM/IgG 23366, 23717 in water (samples #3,
11, #7,#4) was  done. In order to get sufﬁcient volume CHIK sero
gG/IgM 322014 (#9) and sample #5 were diluted. Samples #1 and
10 represented serum of an acute phase (IgM) and of the con-
alescence phase (IgG) of the CHIKV infection. To investigate the
roﬁciency of laboratories concerning cross reaction we chose anti-
odies to West Nile virus (WNV), Ross River virus (RRV) and DENV-2
samples #6, #12, #8). Two negative human plasma samples #13,
2 were included for control purposes.l Virology 76 (2016) 55–65
All samples of infected patients (CHIKV, RRV) used were taken
for routine diagnostic purpose under the national ethical regula-
tion with patient’s consent. Dengue and WNV  antibody positive
sera were obtained from SeraCare (Life Sciences, Milford, MA,  USA).
After aliquoting, coding and freeze-drying sets of EQA samples were
pretested by two  expert laboratories. Control panels of samples
were stored at 4 ◦C (>4 month) and 20 ◦C (4 weeks) and analysed to
monitor the sample integrity.
In September 2014 the EQA panels and instructions (reconstitu-
tion of samples, reporting form) were distributed by regular post.
Laboratories were informed on the anonymous process regarding
the distribution of the summary table of returned results. Labora-
tories providing more than one dataset were listed as (a, b).
3.4. Scoring
For the molecular panel we  applied the following scoring: 2
points for correct results, 1 point equivocal or borderline results,
0 point for false-positive or false negative results. In the case
that the RT-PCR was  false-positive but the associated sequencing
result was  correct, two points were given. The maximal score was
24 points. Quantitative data were not considered for the scoring
procedure. For giving a brief recommendation on the laboratory
performance participants were informed of an “optimal” (all results
were correct), “acceptable” (one false-negative result), or “need for
improvement” (one or more than one false-positive result and/or
more than one false negative result) performance.
The scoring and the classiﬁcation of the serological panel fol-
lowed the EQA for the molecular diagnostic with a maximum score
of 26 points for correct results of 13 samples (Tables 5 and 6). The
laboratory performance analysing the sensitivity and, speciﬁcity of
IgM and IgG antibodies directed against CHIK was analysed sepa-
rately.
4. Results
From a total of 72 laboratories receiving samples 56 laborato-
ries sent back results (60 data sets) for the CHIKV molecular EQA,
corresponding to a response rate of 84.8% compared to 80.8% (42
laboratories) for the serological CHIKV EQA (Table 1). Response
rates of European laboratories with 92.9% for the CHIKV PCR EQA
and 91.4% for the serology EQA were rather high.
The molecular panel for the detection of CHIKV comprised dif-
ferent aspects of quality standards: sensitivity, speciﬁcity, and
genotyping of different CHIKV strains. From 60 data sets, 23 data
sets (38.3%) were classiﬁed as “optimal” with the maximum score
of 24. The classiﬁcation “acceptable” (data sets with only one false-
negative result) was reached by seven (11.7%; scores 22–23). All
data sets had a false-negative or equivocal result for the highest
diluted CHIKV sample. Thirty data sets with scores between 14–22
were classiﬁed as “need for improvement” (50%). Some participants
reported false-positive or equivocal results for other arboviruses
mainly ONNV and DENV-2. Others had one or more false-positive
result and/or two and more false-negative results for the sensi-
tivity test. One laboratory (#53) did not detect samples of CHIKV
Asian genotype while one laboratory (#55) revealed a problem of
contamination in one of two negative samples.
Participating laboratories used conventional in-house RT-
PCR/in-house real-time RT-PCR (78.3%) or commercial real-time
RT-PCR tests (21.7%) (Table 2). Conventional in-house RT-PCR tests
had the highest rate of fully correct results. For the lowest virus
load of the dilution series, the conventional Gel-RT-PCR had a low
detection rate of 20%. Commercial real-time RT-PCRs had prob-
lems with detecting virus loads of 1.3 × 105 copies/ml (77%) and
2.2 × 104 copies/ml (85%). Concerning the speciﬁcity of the ana-
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Table 1
Overall laboratory performance of molecular CHIKV EQA.
Sample #2 #9 #4 #12 #10 #6 #7 #1 #11 #8 #3 #5 Score Class
CHIK  Carib CHIK Carib CHIK Carib CHIK Carib CHIK Carib CHIK India CHIK Seych SINDV ONNV DENV-2 neg. plasma neg. plasma
Laboratory/data set N◦ 1,8E + 08 2,4E + 07 1,8E + 06 1,3E + 05 2,2E + 04 1,1E + 08 2,0E + 08 7,5E + 06 1,9E + 04 8,3E + 04 n.d. n.d.
6#, 8#, 10#, 12#, 14#, 26a#, 26b#, 27#, 28b#,
29#, 30#, 31#, 33#, 34#, 37#, 38#, 40#, 41a#,
41b#, 42#, 46#, 49$, 56$
2 2 2 2 2 2 2 2 2 2 2 2 24 A
36§ 2 2 2 2 1 2 2 2 2 2 2 2 23 B
7$, 19#, 25#, 28a§ , 45§ , 47§ 2 2 2 2 0 2 2 2 2 2 2 2 22
1$, 3$, 17$, 23$, 32#, 39$, 48$, 24# 2 2 2 2 2 2 2 2 0 2 2 2 22 C
4$, 9#, 18#, 21#, 22# 2 2 2 2 2 2 2 2 2 0 2 2 22 C
2$ 2 2 2 2 2 2 2 2 0 0 2 2 20 C
5# 2 2 2 2 2 2 2 2 1 1 2 2 22 C
11# 2 2 2 2 2 2 2 2 0 1 2 2 21 C
13# 2 2 2 2 2 2 2 0 0 2 2 2 20 C
20#, 35#, 43#, 51$, 52#, 54# 2 2 2 0 0 2 2 2 2 2 2 2 20 C
55b# 2 2 0 2 0 2 2 2 2 2 2 2 20 C
16# 2 2 2 2 2 2 2 0 0 0 2 2 18 C
50# 2 2 0 0 0 2 2 2 2 2 2 2 18 C
55a$ 2 2 2 0 0 2 2 2 2 2 0 2 18 C
15# 2 2 2 0 0 2 2 2 0 0 2 2 16 C
44# 2 0 0 0 0 2 2 2 2 2 2 2 16 C
53# 0 0 0 0 0 2 2 2 2 2 2 2 14 C
Correct positive result = 2 points, correct negative result = 2 points, false positive result = 0 points, false negative result = 0 points, equivocal result = 1 point; detection systems: # in-house PCR (Real time PCR); $ commercial PCR
(Real  time PCR); §  in-house PCR (Gel-PCR); Classiﬁcation: A = optimal; B = acceptable; C = need for improvement.
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Table 2
CHIKV detection with different PCR technologies.
Sample code Sample identiﬁcation Copy N◦/ml  All data sets n = 60 In-house
conventional
PCR
n = 5
In-house
real-time PCR
n  = 42
Commercial
real-time PCR
n  = 13
Correct results Correct results Correct results Correct results
n % n % n % n %
#2 CHIK Caribbean 1.8E + 08 59 98.3 5 100 41 97.6 13 100
#9  CHIK Caribbean 2.4E + 07 58 96.7 5 100 40 95.2 13 100
#4  CHIK Caribbean 1.8E + 06 56 93.3 5 100 38 90.5 13 100
#12  CHIK Caribbean 1.3E + 05 49 81.7 5 100 33 78.6 11 84.6
#10  CHIK Caribbean 2.2E + 04 41 68.3 1 20 30 71.4 10 76.9
#6  CHIK India 1.1E + 08 60 100 5 100 42 100 13 100
#7  CHIK Seychelles 2.0E + 08 60 100 5 100 42 100 13 100
#1  SINDV 7.5E + 06 58 96.7 5 100 40 95.2 13 100
#11  ONNV 1.8E + 04 46 76.7 5 100 35 83.3 6 46.2
#8  DENV-2 8.3E + 04 50 83.3 5 100 34 81.0 11 84.6
#3  Negative (plasma) – 59 98.3 5 100 42 100 12 92.3
#5  Negative (plasma) – 60 100 5 100 42 100 13 100
Table 3
Laboratory performance versus in-house PCR methods (published or adapted).
Method Publication N◦ of labs using
method
N◦ of labs with correct results/all results
Sensitivitya Speciﬁcityb Geno-typingc
Real-time PCR Panning et al. [26] 8 38/40 21/24 24/24
Laurent  et al. [27] 1 5/5 3/3 3/3
Pastorino et al. [12] 9 42/54 26/27 27/27
Lanciotti et al. [28] 3 13/15 9/9 9/9
Lim  et al. [29] 1 5/5 1/3 3/3
Edwards et al. [30] 3 7/15 9/9 8/9
Pongsiri  et al. [31] 1 5/5 3/3 3/3
Conventional (Gel) PCR Reddy et al. [32] 1 5/5 3/3 3/3
Hasebe  et al. [7] 1 3/5 1/3 3/3
Sanchez  Seco et al. [33] 2 17/20 11/12 12/12
a Include samples: #2; #9; #4; #12; #10.
b Include samples: #1; #11; #8.
c Include samples: #2; #6; #7.
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ysed detection systems ONNV was frequently found positive by
he commercial assays (#11, 46.2%). SINDV was never detected
ut 15.4% of the laboratories had positive reactions for DENV-2.
n-house real-time RT-PCR systems showed the most heterogenic
attern, 100% correct results were reported for the genotype ESCA
nd for the negative control sample. False positive results were
eported for SINDV, DENV-2 and ONNV between 4.8–19%. False
egative results were revealed for all dilutions in the sensitivity
est.
42 laboratories referred to in-house qRT-PCR protocols while
0 participants used published or modiﬁed RT-PCR protocols
Table 3). The real-time RT-PCRs from Panning et al. and Pastorino
t al. were the most widely used methods in this study [12,26].
owever laboratories using the same protocol reported hetero-
eneous results concerning sensitivity and speciﬁcity but correct
enotyping, which indicated problems associated with laboratory
rocedures.
Forty-six and 50 data sets were returned for CHIKV IgG and IgM
erology respectively (Tables 4 and 5). For the detection of IgM anti-
odies 52% of the routine diagnosis was done by IFA, 40% of the
aboratories used ELISA and only 8% of the results performed an
T or multiplex immunoassay. For the detection of IgG antibod-
es most laboratories (58.7%) used IFA, 26.1% used ELISA systems
nd 15.2% of the results were generated by virus neutralisation test
VNT], HIA or multiplex immunoassay (MIA).
The highest score (26, “optimal”) in CHIKV IgM detection was
chieved only by one laboratory while nine data sets scored 24
oints with the classiﬁcation “acceptable”. One laboratory achieved
4 points but had one false-positive result for cross reactive anti-
odies to RRV and thus the attribution “need for improvement”. All
ther laboratories received lower scores (12–22 points) with the
lassiﬁcation “need for improvement”. For IgG serology 20 from
6 data sets show an optimal performance, 2 were acceptable
nd 24 require improvement regarding sensitivity and speciﬁcity
Table 5). The sensitivity of this serological EQA was associated
ith the assay (in-house and commercial) which was  used by
he laboratory (Tables 6 and 7, ). The mostly used type of tech-
ology was the commercial IFA (21) followed by in-house ELISA
11), commercial ELISA (9) and in-house IFA (5), respectively. Other
echniques like VNT (3), HIA (2) and multiplex immunoassay (1)
ere rarely used. IgG antibodies were detected 100% correctly
n sample #1 (IgM/IgG) by all assay types whereas the correct
etection of CHIKV IgM antibodies was lower: 0–76% in all tests
Table 5).
The most frequently used commercial IFA had problems with the
etection of low CHIKV IgM antibody titres while CHIKV IgG was
etected correctly in this dilution series. Whereas in-house ELISA
ests were more sensitive than the commercial ELISA tests – which
ad the lowest percentage of correct results for CHIKV IgM and IgG
ensitivity – they were less sensitive than IFA and VNT. The VNT
ad problems to detect IgM/IgG in the dilution of 1:16. The lack of
peciﬁcity was a minor problem for IgM detection but for the IgG
etection false positive results were seen for all tested arboviruses
n commercial IFA systems (6) and in-house ELISA IgG (1). The
peciﬁcity was good, only a few laboratories reported false-positive
esults for human plasma which were analysed with commercial
LISA tests.
. Discussion
This study represents the second CHIKV EQA distributed to
aboratories worldwide providing a deeper insight in the inter-
aboratory performance and the techniques used for the diagnosis
f CHIKV infections. In conclusion the data indicate that the
ab performance on CHIKV diagnosis was good with room forl Virology 76 (2016) 55–65 59
improvement for some laboratories. The major problem – the
lack of sensitivity and speciﬁcity – remained as found in the
previous EQA (2007) with 31 participating laboratories [23]. The
diagnosis of CHIKV infection is inﬂuenced by several parameters
requiring qualitative test systems with high sensitivity and speci-
ﬁcity. So far the diagnostic of an acute CHIKV infection is done
by molecular detection of virus genome or by serological IgM
detection most often by commercial IFA tests and/or in-house
PCR.
It is of utmost importance that laboratories realise limits of the
test systems which were revealed in this EQA. While rapid anti-
gen tests may  be problematic for the diagnosis of CHIKV infections
[17,19], PCR and serological tests such as ELISA and IFA are often
used in routine diagnostics. Magurano et al. revealed that different
methods for CHIKV diagnosis give heterogeneous results depend-
ing on sampling at different times after onset of the disease which
reﬂects the complex antigen-antibody response in patients mak-
ing high quality diagnosis of CHIKV infections challenging. [34]. In
CHIKV infected humans the viral loads in blood range from 1 × 105
to 1 × 109 viral RNA copies/ml in the viremic phase lasting 5–7
days [22]. Laboratories should be aware that a negative CHIKV PCR
result in a clinical sample might be a problem of low assay sen-
sitivity caused by a low viral load or improper handling of the
sample.
Virus speciﬁc IgM antibodies were detectable 3–8 days after
onset of symptoms immediately followed by IgG antibodies
detectable from the 4th day post onset. Whereas IgG generally
persists for years, also IgM may  persist in few patients for a
longer period. Therefore it is important to analyse the IgM/IgG
status early in patient samples to detect acute primary infections
[18].
Beside the commonly used ELISA and IFA the VNT seems to
be the most speciﬁc and sensitive assay. However it requires
time-consuming procedures, trained staff working under BSL3 con-
ditions, and does not allow differentiation between IgM and IgG
reactivity. Those few laboratories using this in-house assay showed
good performance.
The speciﬁcity of CHIKV diagnosis remains still challenging.
Other arboviruses as well as sera from non-CHIKV arbovirus infec-
tions to be considered for differential diagnostic prove to be a major
problem for cross-reactivity in the molecular as well as in the sero-
logical panel. Although alphaviruses like Ross River virus (RRV)
were not included in this EQA laboratories should be aware of a ﬁrst
reported case of transfusion-transmitted RRV infection in Australia
2014 and Mayaro virus infections in a Dengue outbreak in Brazil
2011–2012 [35,36].
Comparing the results of this CHIKV EQA with the previous
one from 2007 the detection limit of 2 × 104 copies/ml of CHIKV
(Reunion genotype ESCA) found then positive by 16 laboratories
(66.6%) corresponds quite well to the highest CHIKV dilution in
2014 (2.2 × 104 copies/ml, Asian genotype) detected by 68.3% of
laboratories [25]. The detection of false positive samples was a
minor problem in both EQA studies. The speciﬁcity of PCR tech-
niques was recognized by the positive ﬁnding for the ONNV which
was an unexpected but important issue. Since this reactivity was
mostly caused by the commercial molecular assay the manufac-
turer was  informed. This will result in an improvement of the assay
or an explanation in the assay description. Especially notable is the
false positive detection of DENV-2 which was  noticed in 2007 and
2014.
One major issue identiﬁed in the EQAs in 2007 and 2014 was
the lack of sensitivity for IgM, which was consistent [24]. Also in
2007 the most frequently and successfully used technology was
IFA (18), followed by ELISA (9), HAI (3) and few VNT and dot
blot.
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Table 4
Overall laboratory performance on CHIKV IgM detection.
Sample #3 #11 #7 #4 #9 #10 #1 #5 #6 #12 #8 #13 #2 Score Class
CHIK  sero,
IgM/IgG
CHIK sero,
IgM/IgG
CHIK sero,
IgM/IgG
CHIK sero,
IgM/IgG
CHIK sero,
IgM/IgG
CHIK sero,
IgG
CHIK sero,
IgM
CHIK sero,
IgG/IgM
RR Virus,
IgG/IgM
WN
Virus,
IgG/IgM
DEN
Virus-2,
IgG
Neg.
human
plasma
Neg.
human
plasma
Laboratory/data set N◦ 1:2 1:4 1:8 1:16 1:2 1:5 1:4 1:2.5 1:4 1:4 1:4 Undiluted Undiluted
29a#X 2 2 2 2 2 2 2 2 2 2 2 2 2 26 A
6 , 25$, 28#, 35 , 31a* 2 2 2 0 2 2 2 2 2 2 2 2 2 24 B
11#, 30b§ 2 2 2 2 2 0 2 2 2 2 2 2 2 24 B
34a#X, 34b#Y 2 2 2 2 2 2 0 2 2 2 2 2 2 24 B
18a# 2 2 2 2 2 2 2 2 0 2 2 2 2 24 C
2 , 4 , 15 , 23 , 32 , 38 2 2 0 0 2 2 2 2 2 2 2 2 2 22 C
18b 2 2 2 1 2 2 2 1 0 2 2 2 2 22 C
31b§ 2 2 2 0 2 0 2 2 2 2 2 2 2 22 C
42 2 2 0 0 1 2 2 2 2 2 2 2 2 21 C
29b#Y 2 0 1 0 2 2 2 2 2 2 2 2 2 21 C
3 , 8 , 22$, 26 2 0 0 0 2 2 2 2 2 2 2 2 2 20 C
20 2 2 0 0 2 2 2 0 2 2 2 2 2 20 C
33# 2 1 0 0 2 2 2 2 2 2 1 2 2 20 C
40 2 2 0 0 2 2 2 0 2 2 2 2 2 20 C
27a#Y 2 1 1 0 1 2 1 2 2 2 2 2 2 20 C
30a 2 2 2 0 0 2 0 2 2 2 2 2 2 20 C
36 1 2 0 0 2 2 2 0 2 2 2 2 2 19 C
5 2 2 0 0 2 2 0 0 2 2 2 2 2 18 C
7« 2 2 2 0 0 0 0 2 2 2 2 2 2 18 C
9 0 2 0 0 2 2 2 0 2 2 2 2 2 18 C
12 2 0 0 0 0 2 2 2 2 2 2 2 2 18 C
13 2 0 0 0 2 2 2 0 2 2 2 2 2 18 C
43# 0 0 0 0 2 2 2 2 2 2 2 2 2 18 C
27b#X 2 1 0 0 1 2 0 2 2 2 2 2 2 18 C
37a§ 2 2 2 0 2 0 0 0 2 2 2 2 2 18 C
41$ 2 0 0 0 2 2 0 1 2 2 2 2 2 17 C
1 , 14 2 0 0 0 2 2 0 0 2 2 2 2 2 16 C
21 2 0 0 0 2 2 1 0 2 2 2 2 1 16 C
37c$X 1 1 0 0 0 2 0 2 2 2 2 2 2 16 C
10$, 24$, 37b$Y 0 0 0 0 0 2 0 2 2 2 2 2 2 14 C
19 1 0 0 0 1 2 0 0 2 2 2 2 2 14 C
16$ 1 0 0 0 0 0 0 2 2 2 2 2 2 13 C
17$ 0 0 0 0 0 2 0 0 2 2 2 2 2 12 C
Correct positive result = 2 points, correct negative result = 2 points, false positive result = 0 points, false negative result = 0 points, equivocal result = 1 point; 1:50 starting dilution of sample, 1:100 starting dilution of sample.
Detection  system: # in-house ELISA; #X in-house ELISA (1:50); #Y in-house ELISA (1:100); $ commercial ELISA; $X commercial ELISA (1:50); $Y commercial ELISA (1:100);  in-house IFA;  commercial IFA; § in-house VNT;  in-house
MIA;  classiﬁcation: A = optimal; B = acceptable; C = need for improvement
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Table 5
Overall laboratory performance on CHIKV IgG detection.
Sample N◦ #3 #11 #7 #4 #9 #10 #1 #5 #6 #12 #8 #13 #2 Score Class
CHIK  sero
IgM/IgG
CHIK sero
IgM/IgG
CHIK sero,
IgM/IgG
CHIK sero
IgM/IgG
CHIK sero
IgM/IgG
CHIK sero,
IgG
CHIK sero,
IgM/IgG
CHIK sero,
IgM/IgG
RR Virus,
IgM/IgG
WN Virus,
IgM,/IgG
DEN
Virus-2,
IgG
Neg.
human
plasma
Neg.
human
plasma
Data  set 1:2 1:4 1:8 1:16 1:2 1:5 1:4 1:2.5 1:4 1:4 1:4 Undiluted Undiluted
1 , 3, 4 , 6 , 9 , 11§ ,
12 , 13, 14 , 15 ,
17 , 23, 32, 35 ,
38,  40 , 42 , 30a ,
30b§ , 31a
2 2 2 2 2 2 2 2 2 2 2 2 2 26 A
18a #, 18b 2 2 2 2 2 2 2 1 2 2 2 2 2 25 B
21 2 2 2 2 2 2 2 2 2 2 2 2 1 25 C
5 , 31b§ 2 2 2 0 2 2 2 2 2 2 2 2 2 24 C
8 , 20 2 2 2 2 2 2 2 2 2 2 0 2 2 24 C
16$ 2 2 2 2 1 2 2 1 2 2 2 2 2 24 C
24$, 36 2 2 2 2 2 2 2 0 2 2 2 2 2 24 C
26 2 2 2 2 2 2 2 2 2 2 2 1 0 23 C
7 2 2 2 2 0 2 2 2 2 2 0 2 2 22 C
19 2 2 1 0 2 2 2 1 2 2 2 2 2 22 C
27a #Y, 27b #X 2 2 2 2 0 2 2 0 2 2 2 2 2 22 C
37a§ 2 2 2 0 2 2 2 0 2 2 2 2 2 22 C
2 2 2 2 2 2 2 2 2 0 0 0 2 2 20 C
41 2 2 0 0 2 0 2 2 2 2 2 2 2 20 C
25$ 2 2 0 0 0 2 2 0 2 2 2 2 2 18 C
28 # 2 2 0 0 2 0 2 2 0 2 2 2 2 18 C
22$ 2 0 0 0 0 0 2 0 2 2 2 2 2 14 C
10$, 34 , 37b$Y, 37c$X 0 0 0 0 0 0 2 0 2 2 2 2 2 12 C
43 # 0 0 0 0 0 0 2 0 2 2 2 2 2 10 C
Correct positive result = 2 points, correct negative result = 2 points, false positive result = 0 points, false negative result = 0 points, equivocal result = 1 point; 1:50 starting dilution of sample, 1:100 starting dilution of sample.
Detection system: # in-house ELISA; #X in-house ELISA (1:50); $Y in-house ELISA (1:100); $ commercial ELISA; $X commercial ELISA (1:50); $Y commercial ELISA (1:100);  in-house IFA;  commercial IFA; § in-house VNT;  in-house
MIA;  in-house HIA; Classiﬁcation: A = optimal; B = acceptable; C = need for improvement
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Table 6
CHIKV IgM detection with different technology types.
Sample code Sample
identiﬁcation
Dilution Total data sets
n  = 50
ELISA IFA In-house VNT
n  = 3
In-house
MIA
n = 1
In-house
n = 11
Commercial
n = 9
In-house
n = 5
Commercial
n = 21
n % n % n % n % n % n % n %
#3 CHIK sero,
IgM/IgG,
23366, 23717
1:2 40 80.0 10 90.9 3 33.3 3 60.0 20 95.2 3 100.0 1 100.0
#11  CHIK sero,
IgM/IgG,
23366, 23717
1:4 28 56.0 6 54.5 1 11.1 3 60.0 14 66.7 3 100.0 1 100.0
#7  CHIK sero,
IgM/IgG,
23366, 23717
1:8 16 32.0 6 54.5 1 11.1 0 0.0 5 23.8 3 100.0 1 100.0
#4  CHIK sero,
IgM/IgG,
23366, 23717
1:16 6 12.0 5 45.5 0 0.0 0 0.0 0 0.0 1 33.3 0 0.0
#9  CHIK sero,
IgG/IgM,
322014
1:2 37 74.0 9 81.8 3 33.3 3 60.0 18 85.7 3 100.0 1 100.0
#10  CHIK sero, IgG,
16459
1:5 44 88.0 10 90.9 8 88.9 5 100.0 20 95.2 0 0.0 1 100.0
#1  CHIK sero,
IgG/IgM, 17089
1:4 31 62.0 7 63.6 2 22.2 3 60.0 16 76.2 2 66.7 0 0.0
#5  CHIK sero,
IgG/IgM,
322014
1:2.5 36 72.0 11 100.0 7 77.8 1 20.0 15 71.4 2 66.7 0 0.0
#6  Ross River
Virus,
IgM, IgG
1:4 49 98.0 10 90.9 9 100.0 5 100.0 21 100.0 3 100.0 1 100.0
#12  WNV, IgG, IgM 1:4 50 100.0 11 100.0 9 100.0 5 100.0 21 100.0 3 100.0 1 100.0
#8  DENV-2, IgG – 49 98.0 10 90.9 9 100.0 5 100.0 21 100.0 3 100.0 1 100.0
#13  Negative
human plasma
– 50 100.0 11 100.0 9 100.0 5 100.0 21 100.0 3 100.0 1 100.0
#2  Negative
human plasma
– 49 98.0 11 100.0 9 100.0 5 100.0 20 95.2 3 100.0 1 100.0
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Table 7
CHIKV IgG detection with different technology types.
Sample code Sample identiﬁcation Dilution Total data setsn = 46 ELISA IFA In-house VNTn = 4 Other in-house test
systemsa n = 3
In-house n = 5 Commercialn = 7 In-house n = 5 Commercialn = 22
n % n % n % n % n % n % n %
#3 CHIK sero, IgM/IgG, 23366, 23717 1:2 41 89.1 4 80.0 4 57.1 5 100.0 22 100.0 4 100.0 2 66.7
#11  CHIK sero, IgM/IgG, 23366, 23717 1:4 40 87.0 4 80.0 3 42.9 5 100.0 22 100.0 4 100.0 2 33.3
#7  CHIK sero, IgM/IgG, 23366, 23717 1:8 36 78.3 3 60.0 2 28.6 4 80.0 22 100.0 4 100.0 1 33.3
#4  CHIK sero, IgM/IgG, 23366, 23717 1:16 33 71.7 3 60.0 2 28.6 3 60.0 22 100.0 2 50.0 1 33.3
#9  CHIK sero, IgG/IgM, 322014 1:2 35 76.1 2 40.0 1 14.3 5 100.0 21 95.5 4 100.0 2 66.7
#10  CHIK sero, IgG, 16459 1:5 38 82.6 3 60.0 3 42.9 5 100.0 22 100.0 4 100.0 1 33.3
#1  CHIK sero, IgG/IgM, 17089 1:4 46 100.0 5 100.0 7 100.0 5 100.0 22 100.0 4 100.0 3 100.0
#5  CHIK sero, IgG/IgM, 322014 1:2.5 30 65.2 1 20.0 0 0.0 3 60.0 22 100.0 3 75.0 1 33.3
#6  Ross River Virus, IgM, IgG 1:4 44 95.7 4 80.0 7 100.0 5 100.0 21 95.5 4 100.0 3 100.0
#12  WNV, IgG, IgM 1:4 45 97.8 5 100.0 7 100.0 5 100.0 21 95.5 4 100.0 3 100.0
#8  DENV-2, IgG 1:4 42 91.3 5 100.0 7 100.0 5 100.0 18 81.8 4 100.0 3 100.0
#13  Negative human plasma – 45 97.8 5 100.0 7 100.0 5 100.0 21 95.5 4 100.0 3 100.0
#2  Negative human plasma – 44 95.7 5 100.0 7 100.0 5 100.0 20 90.9 4 100.0 3 100.0
a Other test systems included in-house HI test (2x) and in-house multiplex immune assay (1x).
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